Otezla (Apremilast) Distributor
Otezla (Apremilast) acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4) and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells.
Otezla (apremilast) is a prescription medicine approved for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is also approved for the treatment of adult patients with active psoriatic arthritis. It may also be useful for other immune system related inflammatory diseases
Common pack sizes:
